Foretinib
As of the edition of 20 October 2026, Foretinib is a small molecule: in active development; acts on FLT1, FLT3 and FLT4 and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Small molecule
- Registered trials
- 11, 1 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| MET | Hepatocyte growth factor receptor | P08581 |
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
| TEK | Angiopoietin-1 receptor | Q02763 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 6 | 5 | 0 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2005 to now |
| Fosun Pharmaceutical Industrial | Lead sponsor of trials | 2021 to now |